Table 2.
Clinical data of patients with secondary allogeneic hematopoietic stem cell transplantation
| Case | T1 − T2 Time (d) |
Disease status | Donor matching |
Pre-processing regime |
MNC X108/kg |
CD34+ X106/kg |
Granulocyte reconstruction day | Platelets reconstruction day |
GVHD | Other complications | Follow-up time (month) |
Survival condition |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 31 | PR |
Mother 6/10 |
VP16 + MEL + FLU +ATG |
9.7 | 5.7 | 10 | 27 | cGVHD |
CMV (blood) |
49 | Positive |
| 2 | 45 | PR |
Mother 6/10 |
VP16 + MEL + FLU +ATG |
9.5 | 3.06 | 12 | 97 | cGVHD |
EBV (blood) |
49 | Positive |
| 3 | 30 | AD |
Mother 5/10 |
VP16 + BU + Ara-C + FLU + ATG | 8.8 | 6.22 | 11 | 16 |
III GVHD |
TMA | 4 | Negative |
| 4 | 29 | AD |
Mother 5/10 |
VP16 + MEL + FLU +ATG |
7.6 | 5.8 | 11 | 73 |
III GVHD |
TMA | 5 | Negative |
| 5 | 30 | CR |
Bone marrow bank 9/10 |
VP16 + MEL + FLU +ATG |
9 | 5.75 | 19 | 82 | cGVHD |
CMV (blood) |
25 | Positive |
| 6 | 58 | PR |
Bone marrow bank 8/10 |
VP16 + MEL + FLU +ATG |
8.9 | 8.53 | 12 | 18 |
I aGVHD |
CMV (blood) |
57 | Positive |
| 7 | 1364 | CR |
Mother 5/10 |
VP16 + MEL + FLU +ATG + CTX |
9.4 | 6.9 | 10 | 11 |
II aGVHD |
Cystitis | 22 | Positive |
| 8 | 52 | PR |
Mother 5/10 |
VP16 + MEL + FLU +ATG |
9.9 | 4.5 | 14 | 30 |
I aGVHD |
CMV retinitis |
16 | Positive |
| 9 | 40 | CR |
Mother 5/10 |
VP16 + MEL + FLU +ATG + CTX |
9.67 | 5.82 | 12 | 15 | I aGVHD |
CMV (blood) |
10 | Positive |
| 10 | 60 | PR |
Bone marrow bank 9/10 |
VP16 + MEL + FLU +ATG + CTX |
8.57 | 6.42 | 15 | 21 | No sign |
CMV (blood) |
3 | Positive |